BridgeBio Pharma is less shorted than its peer group heading into today's print, with short interest at 10.6% of the free float, while correlated names like NGNE surged 16.6% on the week and the peer median moved 4.3% against BBIO's 3.8% gain. The short position itself has been in steady retreat. From roughly 21.8 million shares in late September, it has fallen to…
BBIO put/call ratio surges to 1.24, four standard deviations above its 20-day mean of 0.26, signaling heavy pre-earnings hedging ahead of July 31 earnings print.
Key data as of 4 Nov 2026
BBIO enters its August 10 earnings report with options traders firmly positioned for upside — a notable contrast to the elevated short interest that has built steadily over the past month. The clearest signal heading…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for BBIO — free to start on ORTEX.
Sign up for free →Open BBIO on ORTEX